IRF7 and nonpapillary renal cell carcinoma: BAP1-deficient tumors exhibited a significant increase in phosphorylated IRF7 protein levels following treatment with JX-594, rather than treatment with the STING agonist, suggesting a relationship between JX-594 and STING expression and activity in ccRCC cells.